Eli Lilly and Company

(New York Stock Exchange)

Top News rankings and signal summaries are processed using AI and may contain errors.

1
Bullish +75

Eli Lilly vs. Novo Nordisk: The Obesity Drug Race Has a New Leader

AI-generated analysis

Eli Lilly and Company (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) reported contrasting quarterly results in early February that have widened the competitive gap between the two giants in the obesity drug market. Lilly's fourth-quarter revenue surged to $19.29 billion, representing a 42.6% year-over-year...

Bullish Signals

  • Q4 revenue hit $19.29B, up 42.6% YoY driven by tirzepatide.
  • Mounjaro Q4 sales reached $7.41B (up 110%), Zepbound added $4.26B (up 123%).
  • Tirzepatide achieves ~20% weight loss, beating Novo's Wegovy (~14%).
  • Lilly expanding manufacturing across Alabama, Pennsylvania, and Europe.
  • Orforglipron approved in U.S., Japan, EU; beat oral semaglutide head-to-head.
  • Retatrutide lost up to 71.2 lbs in Phase 3 trials.
  • Orforglipron oral approval expected mid-2026 after beating oral semaglutide.
  • Lilly trades at 27x forward P/E, reflecting strong growth momentum.
  • Lilly up 27.65% vs. Novo down 39.85% over the past year.

Bearish Signals

  • Revenue down 7.6% YoY; U.S. fell 15%.
  • Operating income slipped 0.53% amid cost pressures.
  • CEO warns of 2026 pricing headwinds in competition.
  • Cut 9,000 jobs; absorbed $8B charges in 2025.
  • Faces structural U.S. pricing pressure and patent expiry.
  • Diabetes market share down 3.6 points to 30.1%.
  • Stock down 39.85% YoY with forward P/E of 11x.
  • Competitor oral tirzepatide outperforms, threatening Novo's launch.
2
Bullish +75

Eli Lilly (LLY) Stock Climbs as China Approves First GLP-1 Weight-Loss Pill

Drug approval Market expansion AI-generated analysis

Eli Lilly (LLY) shares surged nearly 3% in premarket trading after China's National Medical Products Administration approved orforglipron, sold as Foundayo, as the country's first GLP-1 weight-loss pill. This regulatory milestone establishes Lilly as a market leader ahead of competitor Novo Nordisk, whose oral Wegovy...

Bullish Signals

  • Eli Lilly stock hit record high after China approved orforglipron.
  • Foundayo approval places Lilly ahead of Novo Nordisk in China.
  • Oral therapy expands market beyond injectable users with patient preference.
  • Analysts forecast $4.5 billion GLP-1 sales in China within 7 years.
  • Q3 revenue reached $24.4 billion, up 39% on Mounjaro/Zepbound.
3
Bullish +75

Eli Lilly and Company (LLY) Stock: Surges 4.50% as Foundayo Delivers Positive Phase 3 Sleep Apnea Results

Clinical trial results Drug approval AI-generated analysis

Eli Lilly and Company (LLY) shares surged 4.50% to $1,414.93 following the announcement of positive Phase 3 clinical results for its investigational drug Foundayo (orforglipron). The ATTAIN-OSA program evaluated the treatment in adults with moderate-to-severe obstructive sleep apnea and obesity, demonstrating significant efficacy in reducing...

Bullish Signals

  • Stock rallied 4.50% on Foundayo Phase 3 success.
  • Drug cut sleep apnea events by 43.8% in non-PAP users.
  • Foundayo achieved >11% weight loss, aiding obesity management.
  • Trials showed BP and inflammation improvements for cardiometabolic value.
  • FDA submission planned by Dec 2026 to expand indications.

Bearish Signals

  • GI adverse events caused 12.2% discontinuation in non-PAP users.
  • Side effects led to 6.8% discontinuation for PAP therapy users.
4
Very Bullish +85

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

Company update Drug approval Product launch AI-generated analysis

Eli Lilly continues to solidify its dominant position in the global obesity drug market, particularly as rival Novo Nordisk faces investor skepticism regarding its growth strategy. In the burgeoning oral GLP-1 space, Lilly's new drug Foundayo is gaining significant traction, with CEO Dave Ricks reporting...

Bullish Signals

  • Holds 61% U.S. GLP-1 market share, outpacing rivals.
5
Very Bullish +85

Dorsey Wright & Associates Makes New Investment in Eli Lilly and ...

AI-generated analysis

Dorsey Wright & Associates increased its stake in Eli Lilly and Company (NYSE: LLY) by purchasing 508 shares valued at approximately $468,000 during the first quarter. Other institutional investors also adjusted their holdings, with Brighton Jones LLC increasing its position by 22.0% to own 9,597...

Bullish Signals

  • EPS beat: $8.55 vs $6.97 consensus.
  • Revenue surged 55.5% to $19.8B.
  • Net margin hit 34.98%; ROE at 105.77%.
  • Major banks raised targets with Buy ratings.
  • 28 Buy vs 1 Sell analyst rating.
  • Stock trades above 50-day and 200-day moving averages.
  • Institutions accumulating shares; Dorsey Wright increasing position.
  • 2026 EPS guidance $35.50-$37.00 beats expectations.
6
Bullish +75

Eli Lilly stock surges as cheaper drugs unlock a bigger market

Customer growth Drug pricing Earnings report AI-generated analysis

Eli Lilly (LLY) reported a robust third quarter with worldwide revenue rising 39% to $24.4 billion, driven primarily by its obesity drug portfolio. The company highlighted that increased market access through lower realized prices is successfully expanding volume, with global sales volume up 53% despite...

Bullish Signals

  • Sales guidance raised to $91-92B, boosting investor confidence.
  • Global weight-loss volume up 53% despite lower prices.
  • Zepbound revenue hit $5.35B with 49% YoY growth.
  • Stock surged 7.5% to record high, adding $80B cap.
  • Volume growth offset price drops, validating mass-market strategy.

Bearish Signals

  • Realized prices fell 15% globally, trading margin for volume.
  • Rivals like Novo Nordisk and insurer leverage threaten margins.
  • Earnings risk if volume growth fails to offset price drops.
7
Bullish +65

Eli Lilly Stock Rose Nearly 7% to a Record as It Lifted Its 2026 Sales Forecast to as Much as $92 Billion. Here’s Where the Stock Could Go

Drug approval Earnings report Guidance raised AI-generated analysis

Eli Lilly (LLY) shares surged nearly 7% to a record high of $1,373.70 after the company raised its 2026 revenue forecast to between $91 billion and $92 billion. This guidance represents a midpoint increase of approximately $10 billion compared to February estimates, driven primarily by...

Bullish Signals

  • Raised 2026 revenue forecast to $91-$92 billion.
  • Q3 revenue grew 39% YoY to $24.4B.
  • Adjusted EPS of $7.48 beat estimates.
  • GLP-1 expansion drove strong performance.
  • Retatrutide showed double Novo Nordisk weight loss.

Bearish Signals

  • $2B 2026 revenue includes non-recurring milestones.
  • CFO expects 2027 price headwinds to offset volume.
  • Trades at 31x earnings vs Novo Nordisk's 12x.
  • Future guidance raises may become smaller.
8
Bullish +65

3 Massive Catalysts That Could Ignite an Eli Lilly Stock Rally on Oct 29

Drug approval Earnings report Guidance raised AI-generated analysis

Eli Lilly (LLY) is set to report third-quarter earnings on October 29, following a streak of five consecutive EPS beats and a stock price surge of nearly 20% year-to-date. The company's financial performance remains heavily anchored by its blockbuster tirzepatide franchise, with Mounjaro sales climbing...

Bullish Signals

  • Five-quarter EPS beat streak shows consistent execution.
  • Mounjaro sales surged 91% to $9.94B.
  • Zepbound revenue grew 46% to $4.93B.
  • Raised full-year guidance to $85-87B range.
  • International tirzepatide demand exploded with 172% growth.

Bearish Signals

  • Q3 EPS estimates dropped sharply from $9.87 to $6.67 due to IPR&D charges.
  • U.S. Mounjaro pricing declined 9% excluding rebates, pressuring revenue per unit.
  • Novo Nordisk's pricing poses explicit margin risk in the obesity market.
  • Stock rallied 20% YTD, leaving little room for error if Q3 fails.
9
Bullish +65

Eli Lilly vs Pfizer: One Owns the Obesity Market Today, The Other Paid to Compete Tomorrow - 24/7 Wall St.

AI-generated analysis

Eli Lilly (LLY) and Pfizer (PFE) reported contrasting Q1 2026 results, with Lilly dominating the obesity market while Pfizer rebuilds post-pandemic. Lilly generated $19.80B in revenue, a 55.5% increase driven by Mounjaro ($8.66B) and Zepbound ($4.16B), achieving a 65% volume rise despite a 13% price...

Bullish Signals

  • Lilly revenue surged 55.5% to $19.80B.
  • Mounjaro sales jumped 125% to $8.66B.
  • Lilly volume increased 65% for market dominance.
  • Foundayo approved as first oral GLP-1 pill.
  • Analysts target Lilly at $1,215.79.

Bearish Signals

  • Lilly prices fell 13% prioritizing volume over pricing power.
  • Pfizer COVID revenue down: Comirnaty -59%, Paxlovid -62%.
  • Lilly shares cooled 5.37% despite 40.92% one-year gain.
  • Pfizer's $7B Metsera deal needs successful Phase 3 data.
10
Bullish +72

What Was Eli Lilly Telling You Before Its Stock Ran?

Company update Earnings report Production ramp-up AI-generated analysis

Eli Lilly (LLY) has experienced significant stock appreciation driven primarily by the commercial success of its diabetes and obesity drugs, Zepbound and Mounjaro. By mid-2026, these two products accounted for approximately 65% of the company's quarterly revenue, generating $14.9 billion in the quarter ended June...

Bullish Signals

  • Zepbound/Mounjaro revenue hit $14.9B, ~65% of total sales.
  • Manufacturing capacity expanded to resolve prior supply constraints.
  • Operating margins improved to 45.1% in Q2 2025.
  • U.S. revenue grew 33% YoY driven by core drugs.

Bearish Signals

  • Revenue growth slowed to 47.7% YoY in June 2026.
  • U.S. core drug prices fell 9%, pressuring margins.
11
Bullish +72

7,884 Shares in Eli Lilly and Company $LLY Purchased by Amova Asset ...

AI-generated analysis

Amova Asset Management Americas Inc. established a new position in Eli Lilly and Company (NYSE:LLY) during the first quarter, purchasing 7,884 shares valued at approximately $7.25 million. Several other institutional investors, including Maryland Capital Advisors, Osbon Capital Management, Basso Capital Management, Maseco LLP, and E...

Bullish Signals

  • EPS beat: $8.55 vs $6.97 estimate.
  • Revenue hit $19.8B vs $17.82B target.
  • YoY revenue surged 55.5%.
  • Cantor Fitzgerald raised target to $1,350.
  • Truist Financial set objective at $1,370.
  • Guggenheim lifted target to $1,273.
  • ROE stands at 105.77%.
  • 2026 EPS guidance: $35.50-$37.00.

Bearish Signals

  • Zen downgraded from strong-buy to buy.
  • Low 0.6% dividend yield limits income appeal.
12
Bullish +60

Eli Lilly vs Novo Nordisk: The Battle for Obesity Drug Supremacy

AI-generated analysis

Eli Lilly and Novo Nordisk reported divergent Q1 2026 results that highlight a shifting landscape in the obesity drug market. Eli Lilly grew revenue by 55.5% and raised guidance, driven primarily by tirzepatide products Mounjaro and Zepbound, which saw significant year-over-year growth fueled by international...

Bullish Signals

  • Revenue grew 55.5% in Q1 2026.
  • Mounjaro revenue surged 125% to $8.66 billion.
  • Zepbound revenue increased 80% to $4.16 billion.
  • International revenue climbed 81%.
  • Stock price rose 48.98% over the past year.

Bearish Signals

  • Novo Nordisk adjusted sales declined 4% at constant currency.
  • Novo cutting 9,000 jobs due to declining sales.
  • Ozempic US sales fell 11%, Rybelsus dropped 15%.
  • CagriSema REDEFINE 4 trial missed primary endpoint.
  • Wegovy price cut in Jan 2027 pressures margins.
13
Somewhat Bullish +45

The One Thing To Settle Before Buying Eli Lilly Stock

Drug pricing Earnings report Financial outlook AI-generated analysis

Eli Lilly (LLY) reported a 34% increase in U.S. revenue for the third quarter of 2026, driven primarily by surging volumes of its weight-loss drugs Mounjaro and Zepbound. Despite this volume growth, the company's net price per prescription in the U.S. declined by 10% during...

Bullish Signals

  • U.S. revenue rose 34% YoY in Q3 2026.
  • Mounjaro/Zepbound generated over $16B in Q3 2026.
  • Raised full-year 2026 revenue forecast to $91.5B.
  • Secured ~$900M from milestones and rebates in Q3.

Bearish Signals

  • Net price declined 10% in Q3 2026 due to pricing pressure.
  • Patient mix shift to Medicare/Medicaid expected in 2027.
14
Bullish +75

Guggenheim Boosts Eli Lilly Price Target Amid Strong Weight Loss Drug Demand

AI-generated analysis

Guggenheim Capital has raised its price target for Eli Lilly (LLY) to $1,284 from $1,273 while maintaining a Buy rating, driven by strong demand for the company's weight-loss portfolio. The firm updated its financial model based on prescription trends and confirmed that Zepbound will return...

Bullish Signals

  • Guggenheim raised price target to $1,284 citing strong Mounjaro trends.
15
Bullish +65

Got $10,000? Eli Lilly vs. Nvidia: The Better Buy For 2026

AI-generated analysis

Eli Lilly (LLY) reported a blockbuster Q2 2026 quarter with revenue of $22.97 billion, representing a 47.7% year-over-year increase driven primarily by its incretin portfolio. The company's flagship drugs, Mounjaro and Zepbound, generated combined revenue of nearly $15 billion, with international sales surging following regulatory...

Bullish Signals

  • Q2 2026 revenue beat $22.97B, up 47.7% YoY.
  • International Mounjaro sales surged 172% after China NRDL approval.
  • Raised full-year 2026 guidance to $85B-$87B.
  • Analysts raised 2027 EPS estimates to $47.26.

Bearish Signals

  • U.S. pricing power eroding with 9% price decline excluding rebates.
  • Absorbed $2.78B IPR&D charges impacting near-term profitability.
16
Bullish +75

Eli Lilly (NYSE:LLY) Lifts Guidance on Retatrutide Trial Wins

AI-generated analysis

Eli Lilly (NYSE:LLY) raised its full-year revenue guidance following a quarter characterized by strong growth in its metabolic and obesity treatment portfolio. Management attributed this upward revision to sustained demand for existing treatments and positive late-stage trial results for retatrutide, an experimental triple agonist intended...

Bullish Signals

  • Raised full-year revenue guidance on strong quarterly growth.
  • Positive retatrutide trial results support regulatory submission.
  • Closed acquisitions to add oncology and neuroscience assets.
  • Secured UK approval for weight-loss treatment, expanding footprint.
  • Metabolic franchise strength drove raised revenue guidance.
17
Bullish +75

Eli Lilly (NYSE:LLY) Lifts Guidance on Retatrutide Trial Wins

AI-generated analysis

Eli Lilly (NYSE:LLY) raised its full-year revenue guidance following a quarter characterized by strong growth in its metabolic and obesity treatment portfolio. The company highlighted continued robust demand for its existing franchise, which has outpaced even elevated market expectations, driving the upward revision to its...

Bullish Signals

  • Eli Lilly raised full-year revenue guidance after posting strong quarterly growth across its metabolic and obesity treatment portfolio.
  • Positive late-stage trial results for retatrutide support a planned regulatory submission, reinforcing momentum in the company's core franchise.
  • The company closed several pipeline-focused acquisitions during the quarter to bolster assets in oncology, immunology, and other categories.
  • Eli Lilly received regulatory approval for its weight-loss treatment in the United Kingdom, expanding international access.
  • Management cited broad-based demand growth as the primary driver behind the raised revenue guidance trajectory range.
18
Bullish +65

Eli Lilly’s (LLY) Growth Story Keeps Adding Chapters

AI-generated analysis

Eli Lilly (LLY) reported a robust second quarter with revenue surging 48% year-over-year, driven primarily by its GLP-1 weight loss portfolio. The company received a significant regulatory milestone on August 10 when the UK's Medicines and Healthcare products Regulatory Agency approved Foundayo, an oral GLP-1...

Bullish Signals

  • 48% year-over-year revenue growth in Q2.
  • UK approval expands geographic footprint.
  • Raised full-year guidance to $85-$87 billion.
  • Captures needle-averse patients without cannibalization.
  • 80% prescriptions from first-time GLP-1 users.
  • 60% volume growth offset 13% price decline.

Bearish Signals

  • Valuation at 32.47x earnings vs 18.5x sector average.
  • Mounjaro and Zepbound comprise 65% of Q2 revenue.
  • Realized prices fell 13% year-over-year due to cuts.
  • Patent expirations in India, China, Brazil invite generics.
  • Hedge fund ownership dropped from 137 to 132.
19
Bullish +75

Mounjaro manufacturer makes $1 million in profit every 25 minutes

AI-generated analysis

A comprehensive forensic report by BestBrokers reveals that Eli Lilly, the manufacturer of Mounjaro, generates approximately $1 million in profit every 25 minutes. The analysis covers the top 200 public companies by market capitalization and highlights Eli Lilly's exceptional financial performance over the last 12...

Bullish Signals

  • Generates $1M profit every 25 minutes.
  • $412,264 net profit per employee in 2025.
  • Overtaken Novo Nordisk as global weight-loss leader.
  • Top five pharma firms generated over $99B.
20
Somewhat Bullish +45

Eli Lilly (LLY) Stock Dips Following $2.8B AtaiBeckley Acquisition for Depression Treatment Pipeline

AI-generated analysis

Eli Lilly (LLY) shares dipped slightly to $1,155.52 after announcing a strategic acquisition of AtaiBeckley for an upfront payment of $2.8 billion. The deal aims to significantly bolster Lilly's neuroscience division by integrating advanced-stage depression treatments into its existing portfolio, specifically targeting treatment-resistant depression. The...

Bullish Signals

  • FDA Breakthrough Therapy designation for BPL-003.
  • Phase 2b data shows sustained depression improvements.
  • Acquisition strengthens neuroscience capabilities and pipeline.
  • Advanced-stage treatments reduce early discovery risk.
  • VLS-01 progresses through active Phase 2b trial.

Bearish Signals

  • Stock declined 0.10% near daily low.
  • $1.0 billion contingent on uncertain outcomes.
  • Deal finalizes Q3 2026 with long timeline.